Evidence map›Paper›PMID 31914876›Full record

ArticleJournal of the American Heart Association2020

Involvement of Low-Density Lipoprotein Receptor in the Pathogenesis of Pulmonary Hypertension.

Soban Umar, Gregoire Ruffenach, Shayan Moazeni, Mylene Vaillancourt, Jason Hong, Christine Cunningham, Nancy Cao, Sara Navab, Shervin Sarji, Min Li and 6 more

Open access · goldAbstract read
In one paragraph

Article in Journal of the American Heart Association, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.5field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 28 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Soban UmarDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Gregoire RuffenachDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Shayan MoazeniDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Mylene VaillancourtDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Jason HongDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Christine CunninghamDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Nancy CaoDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Sara NavabDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Shervin SarjiDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Min LiDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Lisa LeeDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
Greg FishbeinDepartment of Pathology David Geffen School of Medicine at UCLA Los Angeles CA.
Abbas ArdehaliDepartment of Surgery David Geffen School of Medicine at UCLA Los Angeles CA.
Mohamad NavabDepartment of Medicine David Geffen School of Medicine at UCLA Los Angeles CA.
Srinivasa T ReddyDepartment of Medicine David Geffen School of Medicine at UCLA Los Angeles CA.
Mansoureh EghbaliDepartment of Anesthesiology David Geffen School of Medicine at UCLA Los Angeles CA.
University of California, Los Angeles · US

Funding

Role of miR193 in oxidized lipid induced pulmonary hypertensionR01HL129051 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EGHBALI, MANSOUREH, REDDY, SRINIVASA T. · 2016 to 2019
$2.3M
Role of the Novel MicroRNA-125b in Pulmonary Hypertension Associated with Pulmonary FibrosisK08HL141995 · NHLBI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI UMAR, SOBAN · 2019 to 2023
$879k
NHLBI NIH HHS K08 HL141995NHLBI NIH HHS R01 HL129051
6 · The paper itself

Abstract

Background Recently, we and others have reported a causal role for oxidized lipids in the pathogenesis of pulmonary hypertension (PH). However, the role of low-density lipoprotein receptor (LDL-R) in PH is not known. Methods and Results We examined the role of LDL-R in the development of PH and determined the efficacy of high-density lipoprotein mimetic peptide 4F in mitigating PH. Explanted human lungs and plasma from patients with PH and control subjects were analyzed for gene expression, histological characteristics, and lipoprotein oxidation. Male LDL-R null (LDL-R knockout) mice (12-15 months old) were fed chow, Western diet (WD), WD with 4F, and WD with scramble peptide for 12 weeks. Serial echocardiography, cardiac catheterization, oxidized LDL assay, real-time quantitative reverse transcription-polymerase chain reaction, and histological analysis were performed. The effect of LDL-R knockdown and oxidized LDL on human pulmonary artery smooth muscle cell proliferation was assessed in vitro. LDL-R and CD36 expression levels were significantly downregulated in the lungs of patients with PH. Patients with PH also had increased lung lipid deposits, oxidized LDL, E06 immunoreactivity, and plasma oxidized LDL/LDL ratio. LDL-R knockout mice on WD developed PH, right ventricular hypertrophy, right ventricular dysfunction, pulmonary vascular remodeling, fibrosis, and lipid deposition in lungs, aortic atherosclerosis, and left ventricular dysfunction, which were prevented by 4F. Interestingly, PH in WD group preceded left ventricular dysfunction. Oxidized LDL or LDL-R knockdown significantly increased proliferation of human pulmonary artery smooth muscle cells in vitro. Conclusions Human PH is associated with decreased LDL-R in lungs and increased oxidized LDL in lungs and plasma. WD-fed LDL-R knockout mice develop PH and right ventricular dysfunction, implicating a role for LDL-R and oxidized lipids in PH.

Indexed as

HemodynamicsVascular RemodelingAnimalsApolipoprotein A-ICase-Control StudiesCD36 AntigensCells, CulturedDisease Models, AnimalFibrosisHumansHypertension, PulmonaryLipoproteins, LDLMaleMice, KnockoutPulmonary ArteryReceptors, LDLApolipoprotein A-ICD36 AntigensCD36 protein, humanD-4F peptideLDLR protein, humanLipoproteins, LDLoxidized low density lipoproteinReceptors, LDLlow‐density lipoprotein receptoroxidized lipidsoxidized low‐density lipoproteinpulmonary hypertensionWestern diet

Identifiers

PMID31914876
PMCPMC7033825
OpenAlexW3000173009

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.